- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00018096
The Genetics of Environmental Asthma
May 5, 2008 updated by: National Institute of Environmental Health Sciences (NIEHS)
In this project, we hypothesize that polymorphisms of genes expressed by the airway epithelia in asthmatics following specific airway challenges predispose individuals to the development of asthma.
To test this hypothesis, we identify the genes that are differentially expressed by airway epithelial cells following challenge with stimuli that induce acquired (house dust mite) or innate (LPS) immune responses, and then determine whether polymorphisms in these genes are associated with the development of asthma in a separate, well characterized, familial cohort of asthmatics.
This is a powerful approach that is designed to identify novel genes that are associated with both asthma pathogenesis (differentially expressed in the exposure-response study) and asthma susceptibility (genetically associated with asthma in a linkage/association study).
Study Overview
Detailed Description
The overall goal of this project is to identify genes that are involved in the development of airflow obstruction and airway inflammation in asthmatics, and to determine whether polymorphisms in these differentially expressed genes predispose individuals to develop asthma.
Asthma is a complex genetic disorder that is caused by a number of unique gene-gene and gene-environment interactions.
The search for asthma susceptibility genes has been complicated by the broad clinical phenotype of asthma, the polygenic inheritance pattern of this disease, and the substantial role of environmental exposures in the development and progression of asthma.
Inhaled environmental agents induce several biologic responses in asthmatics; including the induction of acquired and innate immunity that leads to acute and chronic forms of airway inflammation and airway remodeling.
Acquired immune responses to protein antigens, such as house dust mite allergen, often induce type 2 T lymphocyte-driven responses (Th2) which appear to be important in atopic asthma.
Recent studies by our group and others demonstrate that innate immunity, initiated by inhalation of bacterial and viral pathogens, organic dusts, endotoxin or lipopolysaccharide (LPS), air pollution particulate matter, and ozone, can also cause acute and chronic forms of airflow obstruction, airway inflammation, and even airway remodeling.
Emerging evidence indicates that both acquired and innate immune responses in the lung may be influenced by polymorphic genes.
For instance, functional polymorphisms in the IL-4 receptor gene are thought to preferentially stimulate acquired Th2 immune responses to inhaled allergens, and we have recently shown that common co-segregating mutations in TLR4 (a transmembrane receptor for LPS) are associated with diminished airway responsiveness to inhaled LPS.
These observations suggest that environmental challenges can be used to narrow the phenotype of asthma and investigate genetic susceptibility in biologically specific forms of asthma.
Study Type
Interventional
Enrollment (Actual)
176
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Atopic/asthmatic, atopic/non-asthmatic, non-atopic/asthmatic, or non-atopic/non-asthmatic
- Asthma subjects will be required to have either mild or moderate persistent asthma; positive methacholine challenge
- Atopic subjects should have seasonal allergy symptoms requiring medication and have positive skin test to house dust mite and at least 3 additional allergens. Serum IgE level >100.
- Willing/able to give informed consent & adhere to visit/protocol schedules.
- Screening visit laboratory, C-Xray, EKG, results within normal limits
- Women of childbearing potential must have a negative serum pregnancy test
- Screening Pulmonary Function testing above study criteria parameters
Exclusion Criteria:
- Systemic corticosteroid administration for asthma within the previous 90days
- Antibiotic administration within the previous 30 days.
- Viral respiratory infection within the previous 14 days.
- History of severe asthma requiring intubation.
- Occupational exposure to hay or grain dust.
- Significant exposure history to cigarette smoke
- Past or present history of allergen immunotherapy
- Underlying illnesses that may result in altered lung function
- Students or employees under direct supervision by protocol investigators are ineligible
- Subjects allergic to medications used (or potentially used) in the study will be excluded.
- Subjects using aspirin will be excluded
- Subjects who abuse alcohol or illicit substances will be excluded
- Medication use other than for asthma, allergies or contraception
- Other medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
- Nursing mothers
- Other investigational medication within the last 30 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: bronchoscopy
2 bronchoscopies 4 hours apart; The first to instill the 3 experimental biologic agents in separate airways (HDM, LPS and saline-placebo), the second to perform BAL and brush biopsies 4 hours later in the same airways.
|
instillation of interventional products during bronchoscopy each down a different airway, each subject acts as their own control.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
BAL and endobronchial brush biopsy are measured and cell samples are analyzed to identify the genes in airway epithelia and inflammatory cells that are differentially expressed in response to LPS and dust mite antigen.RNA is isolated for gene expression.
Time Frame: 4 hours post first instillation bronchoscopy
|
4 hours post first instillation bronchoscopy
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
post bronchoscopy symptom followup
Time Frame: 48 hours
|
48 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Sundy S. Sundy, MD. PhD., Duke University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2001
Primary Completion (ACTUAL)
December 1, 2007
Study Completion (ACTUAL)
December 1, 2007
Study Registration Dates
First Submitted
July 2, 2001
First Submitted That Met QC Criteria
July 3, 2001
First Posted (ESTIMATE)
July 4, 2001
Study Record Updates
Last Update Posted (ESTIMATE)
May 6, 2008
Last Update Submitted That Met QC Criteria
May 5, 2008
Last Verified
May 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCRR-M01RR00030-0183
- 2357
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Meyer Children's Hospital IRCCSRecruitingAsthma in Children | Asthma Acute | Asthma Crisis | Asthma ChildhoodItaly
-
Tel-Aviv Sourasky Medical CenterThe Dalia and Eli Hurvitz Foundation GrantNot yet recruitingAsthma Attack | Asthma AcuteIsrael
-
University of PittsburghNational Institute of Environmental Health Sciences (NIEHS)RecruitingAsthma Exacerbation | Childhood Asthma | Air Pollution, Risk Reduction Behaviors | Asthma ControlUnited States
-
Vanderbilt University Medical CenterWithdrawnAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
Columbia UniversityChildren's Hospital of Philadelphia; National Heart, Lung, and Blood Institute... and other collaboratorsNot yet recruitingAcute Asthma | Pediatric Asthma | Non-invasive Positive Pressure Ventilation | BiPAPUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsRecruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicSingapore
-
Johann Wolfgang Goethe University HospitalCompleted
-
Children's Hospital Medical Center, CincinnatiNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruiting
-
Forest LaboratoriesCompleted
Clinical Trials on LPS endotoxin, saline, HDM
-
Karolinska InstitutetDanderyd HospitalCompleted
-
University of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Robert J Noveck, M.D.Foundation for the National Institutes of HealthCompleted
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)CompletedAsthma | Rhinitis, Allergic, Perennial | Rhinitis, Allergic, SeasonalUnited States
-
Karolinska InstitutetThe Swedish Research Council; University of California, San Francisco; Swedish... and other collaboratorsCompletedSickness Behavior
-
John SundyTerminated
-
PfizerTerminated
-
Karolinska InstitutetThe Swedish Research Council; University of California, San Francisco; Swedish... and other collaboratorsCompletedSickness Behavior
-
Radboud University Medical CenterCompletedSepsis | Endotoxemia | Systemic Inflammation | ImmunosuppresionNetherlands
-
Radboud University Medical CenterCompletedInnate Immune ResponseNetherlands